Bargain hunting in a rocky market; plus advantage, CMS

Part two of BioCentury’s 2022 Financial Markets Preview, access to Alzheimer’s mAbs, and translational highlights from the Distillery

Investors enter 2022 assessing buying opportunities in stocks that looked overvalued a year ago, hoping to bounce back from a dreary close to 2021. On the latest BioCentury This Week podcast, Associate Editor Stephen Hansen discusses the takeaways from part two of BioCentury’s 2022 Financial Markets Preview, including the outlook for the IPO market and M&A, and Executive Editor Selina Koch explains what’s at stake with CMS’s National Coverage Determination for Aduhelm aducanumab-avwa from Biogen Inc. (NASDAQ:BIIB) and other mAbs for Alzheimer’s disease. And Senior Editor Karen Tkach Tuzman returns for this month’s installment of What’s on Tap in the Distillery, BioCentury’s monthly translational research highlights from preclinical publications that identify near-term opportunities for product development.